Eutropics Gets $1.7M in NCI Funds for PGx Tests | GenomeWeb

NEW YORK (GenomeWeb News) – Eutropics Pharmaceuticals has received two new Small Business Innovation Research award contracts totaling $1.7 million from the National Cancer Institute to fund development of two biomarker-based companion diagnostic assays for use in cancer treatment.

Eutropics has signed a phase II contract valued at $1.5 million to commercially develop its diagnostic assay aimed at multiple myeloma patient management, and a $200,000 phase I contract to develop a profiling diagnostic assay aimed at guiding therapies for patients with acute myelogenous leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.